Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sandoz Group AGSTU:D8Y -0.85%39 Days Payable is 110.66 as of Jun. 2026, which is 13% above its 10-year median of 98.04. GuruFocus rates STU:D8Y with a GF Score™ of 39/100 and a GF Value™ of €51.27 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 925 Drug Manufacturers companies, Sandoz Group AG ranks better than 62.27% on this metric.
The historical rank and industry rank for Sandoz Group AG's Days Payable or its related term are showing as below:
STU:D8Y'
s Days Payable Range Over the Past 10 Years
Min: 81.47 Med: 98.04 Max: 110.71
Current: 110.71
During the past 4 years, Sandoz Group AG's highest Days Payable was 110.71. The lowest was 81.47. And the median was 98.04.
STU:D8Y's Days Payable is ranked better than 62.27% of 925
companies
in the Drug Manufacturers industry
Industry Median: 89.79
vs STU:D8Y: 110.71
Sandoz Group AG's Days Payable
increased
from Jun. 2025 (109.54) to Jun. 2026 (110.66).
It may suggest that Sandoz Group AGdelayed paying its suppliers.
The historical data trend for Sandoz Group AG's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:D8Y vs ZTS, UTHR, VTRS: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sandoz Group AG's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sandoz Group AG Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sandoz Group AG's Days Payable distribution charts can be found below:
* The bar in red indicates where Sandoz Group AG's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Sandoz Group AG's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sandoz Group AG (STU:D8Y) has a Days Payable of 110.66 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sandoz Group AG and its competitors. This is 13% above median its historical median of 98.04. Over the past decade, Sandoz Group AG's Days Payable has ranged from 81.47 to 110.71. According to the industry distribution chart, Sandoz Group AG ranks #349 out of 925 companies in the Drug Manufacturers industry, placing it in the top 37.7%.
Is Sandoz Group AG's Days Payable too high?
Sandoz Group AG's current Days Payable of 110.66 is 13% above median its 10-year median of 98.04. Over the past 10 years, this metric has ranged from a low of 81.47 to a high of 110.71. The Drug Manufacturers industry median Days Payable is 89.79. Sandoz Group AG's value of 110.66 is 23.2% above this industry median. Based on the distribution chart, Sandoz Group AG ranks #349 out of 925 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Sandoz Group AG has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sandoz Group AG's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sandoz Group AG ranks #349 out of 925 companies for Days Payable. This puts Sandoz Group AG in the upper half of its industry. The industry median Days Payable is 89.79. Sandoz Group AG's value of 110.66 is 23.2% above this benchmark. Historically, Sandoz Group AG's own Days Payable has ranged from 81.47 to 110.71 over the past decade. While the company's 10-year median is 98.04 vs. the industry median of 89.79, Sandoz Group AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 89.79, based on 925 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sandoz Group AG's current Days Payable of 110.66 is 23.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sandoz Group AG and its competitors. For the Drug Manufacturers industry, the median Days Payable is 89.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sandoz Group AG's current Days Payable is 110.66, which is 13% above median its own 10-year median of 98.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sandoz Group AG stock overvalued right now?
Based on GuruFocus' analysis, Sandoz Group AG (STU:D8Y) is currently considered Significantly Overvalued. The stock's GF Value™ is €51.27, compared to a current price of €77.16 — trading 50.5% above its estimated fair value. The current Days Payable is 110.66, which is 13% above median its 10-year median of 98.04 and 23.2% above the Drug Manufacturers industry median of 89.79. Sandoz Group AG's overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Sandoz Group AG (STU:D8Y), the current Days Payable is 110.66 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sandoz Group AG (STU:D8Y) Overvalued in 2026?
Based on GuruFocus' analysis, Sandoz Group AG stock appears to be overvalued.
The current stock price of €77.16 is trading 50.5% above its estimated GF Value™ of €51.27.
GuruFocus considers Sandoz Group AG to be Significantly Overvalued.
Key valuation signals for STU:D8Y:
Days Payable: 110.66 (13% above median its 10-year median of 98.04)
GF Value™: €51.27 vs. price of €77.16 (50.5% above fair value)
Industry Position: 23.2% above the Drug Manufacturers median (#349 of 925)
No single metric tells the full story. See the STU:D8Y stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $11 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among the leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006, as well as the first US biosimilar, Zarxio, in 2015. It has over 10 launched biosimilars in a number of markets and over 20 assets in its pipeline.
39GF Score
Get the complete analysis for STU:D8Y
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:D8Y has been successfully added to your 
